Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers medicines in various therapeutic areas, including gastroenterology; cancer; neurological and psychiatric diseases; and rare diseases, such as immunology and hematology, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Show More...
-
Website http://www.takeda.com
-
Sector Healthcare
-
Industry Drug Manufacturers-Specialty & Generic
-
Last Quote 24.75 EUR
-
Last Updated 18-04-2024
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-03 2011-03 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 TTM Earnings Per Share JPY 377.14 313.96 157.26 188.17 134.95 -185.37 101.71 146.26 237.56 112.86 -69.06 Dividends JPY 180.0 180.0 180.0 180.0 180.0 180.0 180.0 180.0 180.0 180.0 Payout Ratio % * 57.3 73.7 138.7 137.6 266.8 106.6 74.5 128.9 637.1 Shares Mil 789.0 789.0 790.0 790.0 790.0 786.0 788.0 786.0 787.0 967.0 1.549 Book Value Per Share * EUR 22.56 22.16 21.68 21.33 24.51 21.03 21.24 20.57 10.55 25.53 Free Cash Flow Per Share * EUR 2.19 3.18 2.88 0.38 1.43 1.2 -1.13 2.27 2.27 Return on Assets % 10.67 8.84 3.9 3.48 2.5 -3.29 1.97 2.81 4.42 1.21 -0.14 Financial Leverage (Average) 1.33 1.33 1.78 1.83 1.85 2.01 1.96 2.3 2.06 2.69 2.67 Return on Equity % 14.41 11.77 6.05 6.29 4.61 -6.33 3.92 5.98 9.6 3.05 -0.37 Return on Invested Capital % 14.26 11.66 5.16 4.59 3.1 -4.15 3.13 4.3 5.99 1.99 0.78 Interest Coverage 291.99 279.33 135.08 40.03 6.17 -3.42 4.78 7.17 7.8 2.97 0.56 Current Ratio 3.67 3.63 1.7 2.37 1.98 1.49 1.6 0.92 1.46 1.22 1.18 Quick Ratio 2.72 2.68 1.04 1.46 1.61 1.16 1.16 0.6 1.09 0.56 0.68 Debt/Equity 0.010 0.010 0.16 0.26 0.29 0.29 0.28 0.32 0.49 0.92 0.95